Unknown

Dataset Information

0

Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.

ABSTRACT: We demonstrate that a poly(lactide-co-glycolide) (PLG) cancer vaccine can be used in combination with immune checkpoint antibodies, anti-CTLA-4 or anti-PD-1, to enhance cytotoxic T-cell (CTL) activity and induce the regression of solid B16 tumors in mice. Combination therapy obviated the need for vaccine boosting and significantly skewed intratumoral reactions toward CTL activity, resulting in the regression of B16 tumors up to 50 mm(2) in size and 75% survival rates. These data suggest that combining material-based cancer vaccines with checkpoint antibodies has the potential to mediate tumor regression in humans.

SUBMITTER: Ali OA 

PROVIDER: S-EPMC4740221 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.

Ali Omar A OA   Lewin Sarah A SA   Dranoff Glenn G   Mooney David J DJ  

Cancer immunology research 20151215 2

We demonstrate that a poly(lactide-co-glycolide) (PLG) cancer vaccine can be used in combination with immune checkpoint antibodies, anti-CTLA-4 or anti-PD-1, to enhance cytotoxic T-cell (CTL) activity and induce the regression of solid B16 tumors in mice. Combination therapy obviated the need for vaccine boosting and significantly skewed intratumoral reactions toward CTL activity, resulting in the regression of B16 tumors up to 50 mm(2) in size and 75% survival rates. These data suggest that com  ...[more]

Similar Datasets

Unknown Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects.
| S-EPMC7418776 | biostudies-literature
Unknown Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.
| S-EPMC3054015 | biostudies-literature
Unknown Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
| S-EPMC5777502 | biostudies-other
Unknown Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.
| S-EPMC3273624 | biostudies-literature
Unknown Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
| S-EPMC7706287 | biostudies-literature
Unknown Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
| S-EPMC8262093 | biostudies-literature
Unknown CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
| S-EPMC8776878 | biostudies-literature
Unknown Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
| S-EPMC5539354 | biostudies-literature
Unknown The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.
| S-EPMC6190749 | biostudies-literature
Unknown Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
| S-EPMC4588295 | biostudies-literature